Clinical Trial Update: An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating two doses of SSR149415 in outpatients with major depressive disorder has completed, summarizing the efficacy and tolerability results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SSR149415

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder | Phase 2 | Status: COMPLETED